文献速递泌尿男性生殖肿瘤

原发肾细胞癌超低分次立体定向消融放疗:FASTRACK试验汇总分析5年结局

Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials.
PubMed 文献 · Lancet Oncol · 2026-05-17

该汇总分析纳入FASTRACK和FASTRACK II两项前瞻性试验中因医学原因无法手术或手术高风险的原发肾细胞癌患者,评估超低分次立体定向消融放疗(SABR)的长期疗效与安全性。结果表明SABR对较大原发肾肿瘤具有持久局部控制和低严重毒性。

要点

  • 5年局部控制率达98%(89-100),仅1例局部进展。
  • 8%患者出现3级不良事件,均在SABR后2年内发生。
  • 无4级不良事件或治疗相关死亡,支持SABR作为非手术候选者的选择。

核心结论

  • 对不适合手术的较大原发肾细胞癌,SABR显示长期局部控制且严重不良事件率低。
  • 结果支持在可手术患者中开展SABR与手术比较的随机试验。

研究设计与样本

  • 汇总FASTRACK(单中心、1期、前瞻性)和FASTRACK II(国际、非随机、2期)两项临床试验数据。
  • 纳入原发肾细胞癌、医学不可手术或手术高风险、ECOG评分≤2、肿瘤最大径≤10 cm、N0-N1患者。
  • FASTRACK II中≤4 cm肿瘤和FASTRACK中<5 cm肿瘤接受单次26 Gy,较大肿瘤接受42 Gy分3次、间隔48小时。

主要发现

  • 1年局部控制率100%,3年98%(89-100),5年98%(89-100)。
  • 仅1例患者在28个月时出现局部和远处同时进展。
  • 8例(8%)发生3级不良事件:腹痛或胁腹痛4例(4%)、恶心或呕吐2例(2%)、结肠梗阻2例(2%)、乏力1例(1%)、结肠炎或腹泻1例(1%)。
  • 所有3级及以上不良事件均在SABR后2年内发生;无4级不良事件或治疗相关死亡。

关键数值与推荐

  • 局部控制定义:无局部进展,按RECIST 1.1评估。
  • 肿瘤≤4 cm(FASTRACK II)或<5 cm(FASTRACK)接受单次26 Gy;较大肿瘤接受42 Gy分3次。
  • 5年局部控制率98%(89-100);3级不良事件率8%。

临床怎么用

  • 对于医学不可手术或手术高风险的原发肾细胞癌患者,SABR可作为非侵入性治疗选择。
  • SABR后严重不良事件多在2年内出现,需在此期间密切监测。
  • 可手术患者中SABR与手术的比较尚需随机试验验证。

局限性

  • 为两项试验的汇总分析,非随机对照,样本量有限(103例分析)。
  • 未收集种族和族裔数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic ablative body radiotherapy (SABR) is a non-invasive therapy for inoperable primary renal cell carcinoma. However, long-term prospective clinical trial data are scarce. We aimed to use pooled data from two clinical trials (FASTRACK and FASTRACK II) to evaluate activity and safety of SABR in the long term. METHODS: In this pooled analysis, we used data from FASTRACK, a single-institutional, phase 1, prospective clinical trial conducted at the Peter MacCallum Cancer Centre (Melbourne, VIC, Australia), and FASTRACK II, an international, non-randomised, phase 2 clinical trial conducted in seven academic hospitals in Australia and one in the Netherlands. The treatment protocol, inclusion and exclusion criteria, and dose constraints were the same in both trials. Patients had primary renal cell carcinoma and were deemed medically inoperable or high-risk for surgery, were aged 18 years or older, had an Eastern Cooperative Oncology Group performance status of 2 or less, tumours of 10 cm or less in maximal dimension, and N0-N1 disease. Tumours 4 cm or smaller in FASTRACK II and smaller than 5 cm in FASTRACK received a single fraction of 26 Gy and larger tumours received 42 Gy in three fractions 48 h apart. Local control (freedom from local progression) was the primary endpoint, assessed using Response Evaluation Criteria in Solid Tumours (version 1.1) criteria. The analyses were conducted only in patients who commenced protocol treatment. Safety was evaluated with the Common Terminology Criteria for Adverse Events in participants who started protocol treatment. A patient representative was involved in the study design and conduct of FASTRACK II. Both trials were registered with ClinicalTrials.gov (FASTRACK: NCT01676428; FASTRACK II: NCT02613819) and are both completed. FINDINGS: 108 patients were enrolled between June 28, 2012, and Oct 17, 2014 (FASTRACK), and between July 28, 2016, and Feb 27, 2020 (FASTRACK II). Five patients did not receive treatment (one opted for surgery, three did not meet dose constraints and were withdrawn, and one died before treatment). Median age was 76·9 years (IQR 70·0-81·9). 74 (72%) of 103 patients analysed were male and 29 (28%) were female. Race and ethnicity data were not collected. The median follow-up was 5·0 years (IQR 2·3-6·0). Local control at 1 year was 100%, at 3 years was 98% (89-100), and at 5 years was 98% (89-100), with local progression occurring in only one patient who had both local and distant progression at 28 months. Eight (8%) patients had grade 3 adverse events: abdominal or flank pain (four [4%] patients), nausea or vomiting (two [2%]), colonic obstruction (two [2%]), fatigue (one [1%]), and colitis or diarrhoea (one [1%]). All grade 3 or worse adverse events occurred within 2 years of SABR delivery. No grade 4 adverse events or treatment-related deaths were reported. INTERPRETATION: This pooled analysis from two clinical trials of SABR in patients with larger primary kidney tumours unsuitable for surgery supports evidence of long-term local control and low rate of severe adverse events. These results support further investigation through a randomised trial comparing SABR with surgery in select operable patients. FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Siva S, Ali M, Hardcastle N, et al. Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials. Lancet Oncol. 2026. PMID: 42144019. doi:10.1016/S1470-2045(26)00170-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。